यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

vmd n.v. - тулатромицин - antibacterials for systemic use, macrolides - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. Наличието на болестта в стадото трябва да бъде установено преди метафилактичното лечение. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. Наличието на болестта в стадото трябва да бъде установено преди метафилактичното лечение. the product should only be used if pigs are expected to develop the disease within 2–3 days. Овца: лечение на ранните стадии на инфекцията pododermatitis (копытная гниене), свързани с вирулентным пилей dichelobacter nodosus, които изискват системно лечение.

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

dechra regulatory b.v. - тулатромицин - Антибактериални средства за системна употреба - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. Наличието на болестта в стадото трябва да бъде установено преди метафилактичното лечение. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. Наличието на болестта в стадото трябва да бъде установено преди метафилактичното лечение. the product should only be used if pigs are expected to develop the disease within 2–3 days. Овца: лечение на ранните стадии на инфекцията pododermatitis (копытная гниене), свързани с вирулентным пилей dichelobacter nodosus, които изискват системно лечение.

बुल्गारिया - बुल्गारियाई - БАБХ (Българска агенция по безопасност на храните)

Асклеп- фарма ООД - Бактериите pasteurella multocida условия А,нига.,щам НКТЦ 12177, бактерии, pasteurella multocida, серотипа 6v, Инак., щам сест 962, mannheimia haemolytica, серотип А1, Инак. щам atcc 33365,mannheimia haemolytica,серотип А2, Инак.,щам сест 924 - инжекционна суспензия - ≥ 10 на 4 степен dp50; ≥ 10 на 4 степен dp50; ≥ 41, 08 ue; ≥ 41, 08 ue - говеда, овце, свине

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

pfizer limited - дофлоксацин - Антибактериални средства за подаване на заявления, противоинфекционные за подаване на заявления, - turkeys; dogs; cattle; chicken - Пилета:за лечение на хронични респираторни инфекции, причинени от чувствителни щамове на escherichia coli и микоплазма галисептикум . Пуйки: За лечение на хронични респираторни инфекции, причинени от чувствителни щамове на escherichia coli и mycoplasma gallisepticum. Също така за лечение на инфекции, причинени от pasteurella multocida. Куче:за лечение на остра неусложнена инфекция на пикочните пътища, причинени от pseudomonas пръчка или Стафилококком). и повърхностна пиодерма, причинена от staphylococcus intermedius. Размножаване:за лечение на респираторни заболявания едър рогат добитък (доставка треска, хайвер пневмония), причинени от един или смесени инфекции, бактерии pasteurella haemolytica, бактерии pasteurella multocida и / или Микоплазма спп.

बुल्गारिया - बुल्गारियाई - БАБХ (Българска агенция по безопасност на храните)

intervet international b.v - Респираторно-синцитиальный вирус от едър рогат добитък (brsv), нига., щам ev908, parainfluenza-3 вирусни, Инак., щам sp-4 Райзингер, mannheimia (бактерии, pasteurella) haemolytica setotype А1, Инак., щам m4/1 - инжекционна суспензия - най-малко 10 на степен 5, 5 tcid50 - най-много 10 на степен 6, 4 tcid50; най-малко 10 на степен 7, 3 tcid50 - най-много 10 на ст - говеда

बुल्गारिया - बुल्गारियाई - БАБХ (Българска агенция по безопасност на храните)

zoetis belgium sa - С. chauvoei (цялата култура, инактивированная); В. филтри тип b и c (бета-анатоксин); В. филтри тип d (Епсилон анатоксина); В. haemolyticum; В. septicum; ее. septicum анатоксина; ее. нов тип b анатоксина; ее. tetani анатоксина - инжекционна суспензия - 30% v/v that induce at least 90% guinea pig survival; ≥ 13.1 u1; ≥ 7 u1; ≥ 11.7 u2; ≥ 2.8 u1; ≥ 2.1 u1; ≥ 1.6 u1 - говеда, овце

बुल्गारिया - बुल्गारियाई - БАБХ (Българска агенция по безопасност на храните)

zoetis belgium sa - c. perfringens type a toxoid, c. perfringens type b & c (β) toxoid, c. perfringens type d (ε) toxoid, c. chauvoei whole culture, c. novyi toxoid, c. septicum toxoid, c. tetani toxoid, c. sordellii toxoid, c. haemolyticum toxoid - инжекционна суспензия - ≥ 0, 9 u на степен 3, ≥ 12, 4 u на степен 1, ≥ 5, 1 u на степен 1, meets ph eur. ; ≥ 1, 2 u на степен 1, ≥ 3, 6 u на степен 1, ≥ - говеда, овце

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab - melanoma; hodgkin disease; carcinoma, renal cell; carcinoma, non-small-cell lung; carcinoma, transitional cell; squamous cell carcinoma of head and neck; urologic neoplasms; mesothelioma; colorectal neoplasms - Антинеопластични средства - melanomaopdivo as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older. relative to nivolumab monotherapy, an increase in progression free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression. adjuvant treatment of melanomaopdivo as monotherapy is indicated for the adjuvant treatment of adults and adolescents 12 years of age and older with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection. non-small cell lung cancer (nsclc)opdivo in combination with ipilimumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. opdivo as monotherapy is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer after prior chemotherapy in adults. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. malignant pleural mesothelioma (mpm)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. neoadjuvant treatment of nsclcopdivo in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have pd-l1 expression ≥ 1%. renal cell carcinoma (rcc)opdivo as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults. opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with intermediate/poor risk advanced renal cell carcinoma. opdivo in combination with cabozantinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma. classical hodgkin lymphoma (chl)opdivo as monotherapy is indicated for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant (asct) and treatment with brentuximab vedotin. squamous cell cancer of the head and neck (scchn)opdivo as monotherapy is indicated for the treatment of recurrent or metastatic squamous cell cancer of the head and neck in adults progressing on or after platinum based therapy. urothelial carcinomaopdivo as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum containing therapy. adjuvant treatment of urothelial carcinomaopdivo as monotherapy is indicated for the adjuvant treatment of adults with muscle invasive urothelial carcinoma (miuc) with tumour cell pd-l1 expression ≥ 1%, who are at high risk of recurrence after undergoing radical resection of miuc. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)opdivo in combination with ipilimumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy. oesophageal squamous cell carcinoma (oscc)opdivo in combination with ipilimumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%. opdivo as monotherapy is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy. adjuvant treatment of oesophageal or gastro-oesophageal junction cancer (oc or gejc)opdivo as monotherapy is indicated for the adjuvant treatment of adult patients with oesophageal or gastro-oesophageal junction cancer who have residual pathologic disease following prior neoadjuvant chemoradiotherapy. gastric, gastro‑oesophageal junction (gej) or oesophageal adenocarcinomaopdivo in combination with fluoropyrimidine- and platinum-based combination chemotherapy is indicated for the first‑line treatment of adult patients with her2‑negative advanced or metastatic gastric, gastro‑oesophageal junction or oesophageal adenocarcinoma whose tumours express pd-l1 with a combined positive score (cps) ≥ 5.

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

pinnacle biologics b.v.  - натрий porfimer - Хранопровод На Барет - Антинеопластични средства - Фотодинамична терапия (ФДТ) с photobarr е предназначен за: премахване на тежка дисплазия (ГГД) при пациенти с хранопровода на Барет (БО).

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

eli lilly and company limited - употреба, милбемициноксима - Антипаразитни средства, инсектициди и репеленти, endectocides - Кучета - За лечение и предпазване от бълхи (ctenocephalides Фелиз) паразитози при кучета, където един или повече от следните симптоми са необходими едновременно: профилактика на дирофилариоза болест (Л3, Л4 сърдечни червеи);профилактика на angiostrongylosis за сметка на намаляване на нивото на заразяване незрели възрастни (Л5) angiostrongylus vasorum;лечение на стомашно-чревни нематоди на инфекции, причинени от hookworms (Л4, незрели възрастни, Л5) и възрастни ancylostoma сатпит), кръгли червеи (незрели възрастни l5 и възрастни Тохосага canis и toxascaris leonina ограничено възрастен) и власоглава (възрастни власоглавы vulpis).